August 2010: Pulmonary embolism at CT angiography; Nonalcholic fatty liver disease
ARTICLES DISCUSSED:
Pulmonary embolism at CT angiography: implications for appropriateness, cost, and radiation exposure in 2003 patients. Radiology 2010;256(2); Pulmonary CT angiography in patients suspected of having pulmonary embolism: case finding or screening procedure? Radiology 2010;256(2); Nonalcoholic fatty liver disease: detection of elevated nicotinamide adenine dinucleotide phosphate with in vivo 3.0-T 31P MR spectroscopy with proton decoupling. Radiology 2010;256(2). (Source: Radiology Podcasts)
Source: Radiology Podcasts - June 25, 2010 Category: Radiology Authors: webmaster at rsna.org Tags: Podcasts Source Type: podcasts
Long-Term Follow-Up of Patients With Nonalcoholic Fatty Liver
February 2009 (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - February 3, 2009 Category: Gastroenterology Authors: AGA Institute Source Type: podcasts
International Stem Cell Corporation Announces a Manufacturing and Supply Agreement with Millipore Co
International Stem Cell (OTCBB:ISCO) announced today it has entered into a worldwide distribution agreement with Millipore Corporation (NYSE: MIL) to manufacture living cells and cell culture products to be sold through Millipore’s distribution network.
“To work with a company such as Millipore that has sales of over $1.5 billion and is known throughout the world is a wonderful opportunity for ISCO. This partnership will lead to a significant expansion in ISCO’s revenue generation through the manufacture of high quality cells and cell culture products. Millipore is a leader in the life science industry, with a strong...
Source: International Stem Cell Corporation - September 25, 2008 Category: Stem Cells Authors: internationalstemcell Tags: biotechnology science health medicine parthenogenesis stem cell Source Type: podcasts
International Stem Cell Corporation Arranges $3 Million Equity Financing
OCEANSIDE, Calif.–(BUSINESS WIRE)–International Stem Cell Corporation (OTCBB: ISCO - News) has entered into a subscription agreement with an accredited investor to sell three million dollars ($3,000,000) of Series C Preferred Stock at a price of $1.00 per share. The funding is to occur in three tranches. The first, for $700,000, closed August 20, 2008. The second closing for $1,300,000 is scheduled for September 23, 2008 and the final closing of $1,000,000 is scheduled for December 15, 2008, subject to determination by the investor that no material adverse event has occurred. The investor will ...
Source: International Stem Cell Corporation - September 13, 2008 Category: Stem Cells Authors: internationalstemcell Tags: biotechnology science health medicine Source Type: podcasts
International Stem Cell Corporation Arranges $3 Million Equity Financing
OCEANSIDE, Calif.–(BUSINESS WIRE)–International Stem Cell Corporation (OTCBB: ISCO - News) has entered into a subscription agreement with an accredited investor to sell three million dollars ($3,000,000) of Series C Preferred Stock at a price of $1.00 per share. The funding is to occur in three tranches. The first, for $700,000, closed August 20, 2008. The second closing for $1,300,000 is scheduled for September 23, 2008 and the final closing of $1,000,000 is scheduled for December 15, 2008, subject to determination by the investor that no material adverse event has occ...
Source: International Stem Cell Corporation - September 13, 2008 Category: Stem Cells Authors: internationalstemcell Tags: biotechnology science health medicine Source Type: podcasts
International Stem Cell Corporation Arranges $3 Million Equity Financing
OCEANSIDE, Calif.–(BUSINESS WIRE)–International Stem Cell Corporation (OTCBB: ISCO - News) has entered into a subscription agreement with an accredited investor to sell three million dollars ($3,000,000) of Series C Preferred Stock at a price of $1.00 per share. The funding is to occur in three tranches. The first, for $700,000, closed August 20, 2008. The second closing for $1,300,000 is scheduled for September 23, 2008 and the final closing of $1,000,000 is scheduled for December 15, 2008, subject to determination by the investor that no material adverse event has occurred. The investor will ...
Source: International Stem Cell Corporation - September 13, 2008 Category: Stem Cells Authors: internationalstemcell Tags: biotechnology science health medicine Source Type: podcasts
International Stem Cell Corporation Arranges $3 Million Equity Financing
OCEANSIDE, Calif.–(BUSINESS WIRE)–International Stem Cell Corporation (OTCBB: ISCO - News) has entered into a subscription agreement with an accredited investor to sell three million dollars ($3,000,000) of Series C Preferred Stock at a price of $1.00 per share. The funding is to occur in three tranches. The first, for $700,000, closed August 20, 2008. The second closing for $1,300,000 is scheduled for September 23, 2008 and the final closing of $1,000,000 is scheduled for December 15, 2008, subject to determination by the investor that no material adverse event has occ...
Source: International Stem Cell Corporation - September 13, 2008 Category: Stem Cells Authors: internationalstemcell Tags: biotechnology science health medicine Source Type: podcasts
International Stem Cell Corporation Arranges $3 Million Equity Financing
OCEANSIDE, Calif.–(BUSINESS WIRE)–International Stem Cell Corporation (OTCBB: ISCO - News) has entered into a subscription agreement with an accredited investor to sell three million dollars ($3,000,000) of Series C Preferred Stock at a price of $1.00 per share. The funding is to occur in three tranches. The first, for $700,000, closed August 20, 2008. The second closing for $1,300,000 is scheduled for September 23, 2008 and the final closing of $1,000,000 is scheduled for December 15, 2008, subject to determination by the investor that no material adverse event has occurred. The investor will ...
Source: International Stem Cell Corporation - September 13, 2008 Category: Stem Cells Authors: internationalstemcell Tags: biotechnology science health medicine Source Type: podcasts
Mother Was Right About Cod Liver Oil
George Griffing, MD, Professor of Medicine, St. Louis University, and Editor in Chief of Internal Medicine for eMedicine, explains the truth about cod liver oil. (Source: MedGenMed Weekly Editorials from Medscape.com)
Source: MedGenMed Weekly Editorials from Medscape.com - January 11, 2008 Category: Journals (General) Authors: George T. Griffing, MD Source Type: podcasts
Meet Ken Aldrich the co-founder of International Stem Cell Corporation
Welcome to this podcast. I am Ken Aldrich, Chairman and co-founder of International Stem Cell Corporation.
International Stem Cell Corporation recently announced that our scientific team, led by our Chief Scientist, Dr. Elena Revazova, has created a new class of human stem cell lines that do not involve the use of fertilized eggs and may enable hundreds of millions of people of different sex, ages and racial groups to benefit from cell based therapy with cells that will not be rejected by the patients own immune system after transplanting. The article was published in the on line edition of the well known peer-review publi...
Source: International Stem Cell Corporation - December 30, 2007 Category: Stem Cells Authors: internationalstemcell Tags: biotechnology science health medicine Source Type: podcasts
